Novartis AG (ADR) (NVS)

I bought this one back in April and am very satisfied with the growth. This one is a long term investment with a strong reputation in the biotech industry.

There's always a need for pharmaceuticals and this one at PE 14 looks like a good deal.

Aggressively hired during the recession

Blue-chip leader in the health care area with a broad product line. Low debt, good projected 5 year growth rate and rising dividend gives excellent Total Return potential.

Novartis's acqusition of Alcon guarantees its position as a n international leader in the Pharma/Bio/Med biz

Showed up on a screen for solid 5 year growth with low debt, cash on hand and still at attractive P/E ratios.

It's hard to be blue about a stock that's up 32%, but picking Novartis to outperform the S&P back in Feb. isn't working out so well on CAPS with the S&P up 40%! I still like the call, (and in your portfolio you don't have to beat the S&P!). With margins in the 20% range and annual revenue of $42 Billion, and positive cash flow in the $5 Billion plus range, Novartis may not be outperforming the S&P with it coming off it's fear induced bottom, but it will continue to shine long after the S&P has ran out of steam. It is difficult for drug companies to mantain headway when licenses to core revenue drugs expire and generics infringe on the margins, but Novartis has continued to lead in new drug development and will get an added bonus from the mutating flu strains. Manufacturing for other companies on a contract basis helps shield them from the licensing issues. Veterinary, eye products, OTC drugs, and other diversification also helps. The recession impacts drug companies as well as other industries, but not quite as deeply. The 3.4% dividend will help make Novartis a winner and eventually it will trump the S&P.

Will mirror and follow the S&P. Solid company with no shining star products will provide decent returns but nothing flashy.

Continued improvement in new drug news, expected increases in sales in the pipeline, great dividend growth history, still growing, great earnings growth history. Expect 20-30 % gain in next 6 to 12 months.

The relationship between drugs and the aging population. Need I say more?

I am bearish on the whole pharmaceutical sector. Under the lead of Vasella Novartis has not improved. 30% of income from only two drugs, the patent of one of them close to expire

FLU IS COMING FLU IS COMMMMMMMIIIIING

Another medicine man. They need to back up Sandoze and will be picking up some generic or boosting their generic business some how.

Quality large pharma oversold due to questions regarding healthcare reform.

Hedge against decline in dollar, nice dividend, great company, good position in its industry.

2009 World's Most Ethical Companies:
http://ethisphere.com/wme2009/

Well positioned to do well plus nice dividend, should be good steady earner

Commentary by tenmiles (100.00) + swine flu vacine + biosimiliar OK in Japan.

Yep, Swine Flu, 35 countries making an inquiry for the ingredients in their cell based vaccine. No brainer.